Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer ...
The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of ...
Patients with stage III to IV or recurrent, radiographically apparent EC and no previous chemotherapy or disease progression ≥6 months after neo/adjuvant platinum-based chemotherapy were randomly ...
Clip and Blue—An Easy and Cost-Effective Prechemotherapy Localization Technique in Patients With Breast Cancer Planned for Breast Conservation Uncovering real-world data holds immense potential to ...
A 64-year-old engineer was diagnosed with a cT2cN0M0, Gleason score 8, adenocarcinoma of the prostate. His prostate-specific antigen level was 15 ng/mL. The case was discussed at the hospital tumor ...
Tissue inadequacy and operational challenges may limit lung cancer comprehensive biomarker testing. Here, we describe the initial implementation of a tailored tissue molecular journey at Oncoclínicas ...
Validation of an Updated Algorithm to Identify Patients With Incident Non–Small Cell Lung Cancer in Administrative Claims Databases Although the potential transformative effect of electronic health ...
Embark on an intimate journey with heartfelt narratives, poignant reflections, and thoughtful dialogues, hosted by Dr. Lidia Schapira. The award-winning podcast JCO Cancer Stories: The Art of Oncology ...
Factors Associated With Default of Treatment and Follow-Up Among Patients With Cancer: A Cross-Sectional Study From a Lower-Middle-Income Country This study reports on the current status of Radiation ...
Authors About Careers JCO Resource Centers Breast Cancer Non–Small Cell Lung Cancer Renal Cell Carcinoma Search 0 Cart Log in become a member Quick Search Enter words / phrases / DOI / keywords / ...
The perspective of all stakeholders involved in clinical trials is critical to addressing disparities in racial/ethnic minority (REM) clinical trial participation. Little is known about clinical trial ...
Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial The results of the interim ...